Ultragenyx Pharmaceutical Inc.
RARE
Market Cap$4.17B
Close$
$55.30
27.5% upside
Current Fair Value
27.5% upsideUndervalued by 27.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.17 Billion |
|---|---|
| Enterprise Value | $3.60 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-8.25 |
| Beta | 1.14 |
| Outstanding Shares | 82,300,000 |
| Avg 30 Day Volume | 697,247 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -6.88 |
|---|---|
| PEG | 36.46 |
| Price to Sales | 8.68 |
| Price to Book Ratio | 14.46 |
| Enterprise Value to Revenue | 8.28 |
| Enterprise Value to EBIT | -6.32 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis